Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
25.88
-1.14 (-4.22%)
At close: Feb 20, 2026, 4:00 PM EST
26.55
+0.67 (2.60%)
After-hours: Feb 20, 2026, 5:52 PM EST
Zenas BioPharma Employees
Zenas BioPharma had 130 employees as of December 31, 2024.
Employees
130
Change
n/a
Growth
n/a
Revenue / Employee
$115,385
Profits / Employee
-$1,460,762
Market Cap
1.39B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 130 | 23 | 21.50% |
| Sep 30, 2024 | 115 | 31 | 36.90% |
| Jun 30, 2024 | 114 | 30 | 35.71% |
| Mar 31, 2024 | 107 | - | - |
| Sep 30, 2023 | 84 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Novavax | 952 |
| Immatics | 645 |
| Intellia Therapeutics | 403 |
| uniQure | 209 |
| Capricor Therapeutics | 160 |
| Monte Rosa Therapeutics | 147 |
| AnaptysBio | 136 |
| Savara | 59 |
ZBIO News
- 11 days ago - Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 - GlobeNewsWire
- 16 days ago - Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 4 weeks ago - These 20 stocks are strong choices for momentum investors - Market Watch
- 5 weeks ago - Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Zenas BioPharma, Inc. (ZBIO) Discusses Positive Phase 3 INDIGO Trial Results for Obexelimab in IgG4-Related Disease Transcript - Seeking Alpha
- 6 weeks ago - Why Zenas BioPharma's Selloff Was Structurally Inevitable - Benzinga
- 6 weeks ago - Zenas: Maintaining 'Strong Buy' As Cross-Trial Comparison Of Obexelimab Should Not Be A Factor - Seeking Alpha
- 6 weeks ago - Zenas BioPharma Touts Phase 3 Win, But Stock Crashes - Benzinga